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tation. Methods: Patients with relapsed or refractory Hodgkin’s
disease received cyclophosphamide 4.5 g/m2 for mobilization che-
motherapy, following which they were given G-CSF 10 g/kg/day
subcutaneously until stem cell collection. Patients then received
cyclophosphamide 1.8 g/m2 from day6 to day3, etoposide 800
mg/m2from day 6 to day 4, and carmustine 200 mg/m2 on day
6 and day 5. Beginning on Day 0, G-CSF 5 g/kg/day was
administered. Patients with bulky disease at relapse or multiple (2
or more) recurrences in the same nodal basin(s) after primary or
salvage therapies were eligible to receive consolidative radiother-
apy. Results: 40 patients were enrolled in this study. Thirty-nine
underwent autologous transplantation, with a median age of 31.8
years (range 17.5–74.4 years). Fifteen (37.5%) patients had primary
refractory disease. The median times to neutrophil and platelet
count recovery were 9 and 14.5 days, respectively. Twenty-two
(55%) patients relapsed with a median time to progression of 0.98
years (range 0.2–8.7 years). Overall survival was 50% with a me-
dian follow up of 5.4 years (range 2–8.7 years). Four patients died
of transplant related causes. These were: pulmonary ﬁbrosis, adult
respiratory distress syndrome, myocardial infarction prior to un-
dergoing transplantation, and cryptogenic organizing pneumonitis
(BOOP). Conclusions: Cyclophosphamide, etoposide, and car-
mustine is an effective high dose chemotherapy regimen for the
treatment of relapsed and refractory Hodgkin’s disease. However,
many of these patients unfortunately relapse. Novel approaches to
reduce the risk of relapse such as post transplant immunotherapy
or allogeneic transplantation should be investigated in this patient
population.
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HIGH DOSE MITOXANTRONE AND MELPHALAN FOLLOWED BY AUTOL-
OGOUS STEM CELL TRANSPLANTATION FOR LYMPHOID MALIGNAN-
CIES
Chan, G.W.1, Sprague, K.A.1, Klein, A.K.1, Klingemann, H.G.1 Tufts-
New England Medical Center, Boston, MA.
We evaluated outcomes in 44 patients with lymphoid malig-
nancies who underwent autologous stem cell transplantation
following a preparative regimen of mitoxantrone 20 mg/m2 over
1 hour  3 (total dose 60 mg/m2 ) and melphalan 60 mg/m2
over 1 hour  3 (total dose 180 mg/m2). Twelve patients (6
male) had nodular sclerosing (n  9) or mixed cellularity (n 
3) Hodgkin’s Lymphoma (HL), while 32 patients (17 male) had
diffuse large B-cell (n  21), T-lymphoblastic (n  4), mantle
cell (n  2), T cell rich B-cell (n  1), or anaplastic large cell
(n  3) non-Hodgkin’s lymphoma (NHL). The median age
among Hodgkin’s patients was 35 years (range 19–46 years)
while the median age among NHL patients was 47 years (range
23–63 years). Two patients were in ﬁrst complete remission
(CR), 1 patient in CR2, while 15 patients had partial response,
14 patients had relapsed disease, and 12 patients had refractory
disease at the time of transplant. All patients had a left ventric-
ular ejection fraction of at least 40% at the time of transplant.
Mitoxantrone and melphalan were well tolerated, with grade 3/4
mucositis the most common toxicity. Neutrophil engraftment
was seen at the median of 13 days (range 8–34 days). Day 100
transplant related mortality (TRM) was 3%. The 3-year disease
free (DFS) and overall survival (OS) were 63% and 67%, re-
spectively. Three-year DFS were similar between HL and NHL
patients (67% vs 63%: P  .66). There was no signiﬁcant
difference in 3-year DFS between patients with CR or PR versus
relapsed or refractory disease (66% vs 62%: P  .96). DFS were
similar among all disease subtypes. Congestive heart failure
occurred in on 3 patients (7%). One patient died of complica-
tions from CHF while 2 others recovered cardiac function. In
conclusion, mitoxantrone and melphalan preparative regimen is
well tolerated with minimal cardiac toxicity in patients with
lymphoid malignancies previously treated with anthracyclines.
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DIVIDED DOSE SCHEDULING OF MESNA TO PREVENT THE DEVELOP-
MENT OF CYCLOPHOSPHAMIDE-ASSOCIATED HEMORRHAGIC CYSTITIS
IN AUTOLOGOUS TRANSPLANT PATIENTS
Mc Pheeters, L.3, Kennedy, D.3, Holmberg, L.A.1,2 1. Fred Hutchinson
Cancer Research Center, Seattle, WA; 2. University of Washington
School of Medicine, Department of Medicine, Seattle, WA; 3. University
of Washington School of Medicine, Department of Pharmaceutical Sci-
ences, Seattle, WA.
Cyclophosphamide is an alkylating anti-neoplastic agent used for
mobilization and transplant regimens in ASCT patients. Hemor-
rhagic cystitis (HC) is a possible adverse reaction associated with
cyclophosphamide and may be prevented by the concomitant use
of mesna and intravenous (IV) hydration. Several mesna dosing
schedules have been studied in non-transplant clinical settings;
however, few studies have included ASCT patients. In order to
facilitate administration of cyclophosphamide in the outpatient
setting, and to reduce hospitalizations for continuous bladder irri-
gation, the standard of care at our institution since January 2003
has been to give mesna IV at the same dose of cyclophosphamide
in four equally divided doses at 15 minutes before, then 3, 6, and
8 hours after the administration of cyclophosphamide. A retrospec-
tive review was performed in ASCT patients to evaluate the effec-
tiveness of this mesna dosing schedule with aggressive IV hydra-
tion in preventing the development of HC. Cyclophosphamide
dosing in mobilization regimens was 3–4 gm/m2 and in transplant
regimens was 60–120 mg/kg. Of the 64 patients evaluated, 35
(55%) developed hematuria according to NCI Common Toxicity
Criteria, v. 3.0. Only one patient developed symptomatic HC.
Four patients developed hematuria with concurrent urinary tract
infections. There were no statistical differences between the
groups who did or did not develop HC in terms of age, gender,
underlying malignancy, past medical history, and concurrent use of
medications that place a patient at increased hemorrhagic risk.
More patients developed hematuria after receiving cyclophospha-
mide in transplant regimens than after mobilization regimens (24
vs 11 patients, P  .05). Patients who previously received cyclo-
phosphamide or ifosfamide as conventional chemotherapy were
more likely to develop hematuria (P  .025) after mobilization or
conditioning regimens. Patients were more likely to develop he-
maturia after the transplant regimen if they had a prior history of
receiving cyclophosphamide or ifosfamide (P  .001) with conven-
tional or mobilization chemotherapy. In conclusion, mesna IV
given in four equally divided doses with aggressive IV hydration is
effective in preventing the development of signiﬁcant HC. Addi-
tionally, this regimen facilitated the routine outpatient administra-
tion of high-dose cyclophosphamide.
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INTERLEUKIN 2 (IL-2) AND GRANULOCYTE-MACROPHAGE COLONY
STIMULATING FACTOR (SARGRAMOSTIN) (GM-CSF) FOLLOWING AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (ASCT) FOR
BREAST CANCER
Holmberg, L.A.1,2,3, Bensinger, W.1,2,3 1. Fred Hutchinson Cancer
Research Center, Seattle, WA; 2. University of Washington, Depart-
ment of Medicine, Seattle, WA; 3. Puget Sound Oncology Consortium,
Seattle, WA.
Relapse remains a major problem after autologous stem cell
transplant for advanced breast cancer. GM-CSF has been shown in
vitro to enhance IL-2 mediated tumor lysis. We evaluated if the
addition of IL-2 and GM-CSF early after ASCT would reduce the
risk for relapse and prolong survival, Between April 1998 and April
2002, 50 patients with inﬂammatory stage IIIB (n  18) and
chemo-responsive stage IV (n  32) breast cancer were treated
with high dose Busulfan (12 mg/kg), melphalan (100 mg/m2), and
Thiotepa (500 mg/m2), followed by the infusion of autologous/
syngeneic peripheral blood stem ells (PBSC). Thirty to 100 days
after PBSC infusion after recovering from the acute toxicity of the
myeloablative therapy, patients were scheduled to receive 12 weeks
of IL-2 at 0.6  106 IU/m2 sc daily and GM-CSF 125 ug/m2 sc 3
times per week. All patients also took Tamoxifen 20 mg po qd
during the 12 weeks of immunotherapy. Twenty-six (52%) patients
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received immunotherapy. The reasons for not receiving immuno-
therapy included transplant related death (6%), inadequate recov-
ery for acute toxicity (16%), failure to obtain insurance coverage
(8%), progression of disease (8%), and patient’s/physician’s choice
(10%). The median time to start therapy was 70 days (range
32–100 days). There were no immunotherapy related deaths. By
NCI Common Toxicity Criteria, the following grade 3–4 toxicities
were seen: grade 4 hematological (n 4), grade 3 infection (n 3),
grade 4 circulatory (n  1), grade 4 gastrointestinal (n  1), grade
3 neurological/neuro-central (n  1), and grade 3 dermatology
(n  1). The most common toxicity was erthyema/induration at
injection sites. For all patients, the median follow-up is 50 months.
If one compares the outcome of patients who survived transplant
and did not have early relapse as to whether they received immu-
notherapy or not, the following outcomes were seen. The survival
rate is 63% versus 43% for patients with inﬂammatory disease. For
stage IV disease the median survival without immunotherpy was 20
months versus 39 months with immunotherapy. Median time to
disease progression was 18 months with immunotherpy and 12
months without immunotherapy. Immunotherapy with IL-2 and
GM-CSF is well tolerated after ASCT. Immunotherapy appears to
impact on survival but relapse still remains a problem for patients
with advanced breast cancer after ASCT.
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USE OF PEG-FILGRASTIM OR FILGRASTIM AFTER HIGH DOSE CONDI-
TIONING WITH BEAC CHEMOTHERAPY IN PATIENTS WITH LYMPHOMA
Richart, J.M.1, Kallogjeri, D.1, Oliver, D.A.1, Petruska, P.J.1,
Pincus, S.M.1 Saint Louis University, Saint Louis, MO.
Colony stimulating factors are routinely used after high dose
chemotherapy and autologous transplant. Few data are available
addressing the efﬁcacy of PEG-ﬁlgrastim. Thirty-one consecutive
patients who underwent BEAC conditioning and autologous trans-
plant for lymphoma at a single institution were analyzed. One
patient died prior to neutrophil recovery and is not included in this
analysis. Nineteen patients received ﬁlgrastim either 480 mcg if
they weighed 	60 kg or 300 mcg for a weight 60 kg subcutane-
ously daily starting day 5 and continuing until ANC 	 500.
Eleven patients received 6 mg PEG-ﬁlgrastim on day 1. The
median number of CD34 cells/kg was 3.9 (1.7–8.2) in the ﬁl-
grastim group and 2.9 (1.7–9.1) in the PEG-ﬁlgrastim group. The
median number of prior cytotoxic chemotherapeutic regimens was
1 (1–3) in the ﬁlgrastim group and 1 (1–2) in the PEG-ﬁlgrastim
group. Diagnoses in the ﬁlgrastim group: diffuse large B-cell lym-
phoma (6), follicular lymphoma (7), or mantle cell lymphoma (6).
Diagnoses in the PEG-ﬁlgrastim group: diffuse large B-cell lym-
phoma (2), follicular lymphoma (3), mantle cell lymphoma (3),
anaplastic T cell lymphoma (1), or cutaneous T cell lymphoma (2).
For the ﬁlgrastim group, the median time to neutrophil engraft-
ment was 10 days (9–13); the median time to platelet engraftment
was 10 days (8–15). For the PEG-ﬁlgrastim group the median time
to neutrophil engraftment in was 11 days (8–16); the median time
to platelet engraftment was 14 days (10–16). The median number
of injections in the ﬁlgrastim group was 5 (4–7). Conclusions:
Both ﬁlgrastim and PEG-ﬁlgrastim allow for prompt neutrophil
recovery in patients undergoing BEAC conditioning and autolo-
gous transplant. Factors other than efﬁcacy such as convenience,
patient comfort and cost should be considered when choosing a
post transplant colony stimulating factor.
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DOES GM-CSF ALTER THE PROGNOSTIC SIGNIFICANCE OF EARLY LYM-
PHOCYTE RECOVERY POST-AUTOGRAFTING FOR NHL?
Tiwari, D.1, Vij, R.1, Devine, S.1, DiPersio, J.1, Khoury, H.J.2 1.
Washington University School of Medicine, St. Louis, MO; 2. Emory
University School of Medicine, Atlanta, GA.
Early lymphocyte recovery, assessed by an absolute lymphocyte
count (ALC,	 500/mcl) measured on post-transplant day 15, is an
independent prognostic factor for disease-free and overall survival
after autografting multiple myeloma, NHL, metastatic breast can-
cer, and AML. The effect of post-transplant administration of
myeloid growth factors on the prognostic signiﬁcance of ALC is
unknown. We analyzed the outcomes of 268 relapsed chemo-
sensitive NHL patients autografted at Washington University be-
tween January 1996 and May 2003, divided into 2 groups based on
their day 15 ALC counts (	500, n  151; 500, n  117). All
patients received GM-CSF 250 mcg/kg subcutaneously starting on
day 0 to hasten neutrophils recovery. Patient were well balanced
between the 2 groups with regards to age, gender, preparative
regimen, prior therapy, time from diagnosis to transplant, and
number of CD34 cells infused within each grade. Median fol-
low-up was 22 months. No associations between early lymphocyte
recovery and reduction of post-transplant complications, or im-
provement of disease-free and overall survival were observed. Late
lymphocyte recovery (ALC  500 on day 15) was independently
associated with a delay in platelet recovery (29 vs 21 days, P 
.0005) in patients who have not received pre-transplant rituximab.
We conclude that, in this single-center retrospective analysis, the
favorable prognostic signiﬁcance of post-transplant early lympho-
cyte recovery could not be reproduced and may have been due to
post-transplant administration of GM-CSF.
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EBV-ASSOCIATED POST-TRANSPLANTATION LYMPHOPROLIFERATIVE
DISORDERS; A REPORT OF THREE CASES IN AUTOLOGOUS HSCT PA-
TIENTS OF T CELL LYMPHOMA
Koseki, M.1, Uryu, H.1, Takeuchi, M.1, Matsue, K.1 Kameda Medical
Center, Kamogawa, Chiba, Japan.
Epstein-Barr virus(EBV)-associated post-transplant lymphopro-
liferative disorders(PTLD) mostly occur in solid organ and allo-
geneic hematopoietic stem cell trnasplant(HSCT) patients with
immunosuppression associated with high mortality rate but follow-
ing autologous HSCT is rare complication. We report 3 cases of
PTLD after autologous HSCT for T cell lymphoma. One is
successfully treated with rituximab in durable remission but the
other 2 without rituximab therapy died in aggressive clinical
courses. T cell lymphoma could be a risk factor of developing
PTLD after autologous HSCT due to its speciﬁc T cell dysfunc-
tion. Currently, use of rituximab provides far better outcome that
biopsy conﬁrmed diagnosis should be made in those high risk
patients.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT) A SINGLE CEN-
TER 10 YEARS EXPERIENCE
Guillermo, C.1, Diaz, L.2, Isaurralde, H.1, Topolansky, L.2,
Baubeta, A.1, Lizarralde, A.1, Testa, G.1, Perdomo, S.1, Perdomo, A.1,
Lavagna, G.1, Nese, M.2 1. Centro IMPASA de Trasplante de Medula
Osea CITMO, Montevideo, Uruguay; 2. Hematological Department.
Medicine Department, University of Medicine, Montevideo, Uruguay.
We evaluated the results of SCT at CITMO between 1995 and
2005. We performed 323 SCT; 281 autologous (auto-SCT): 164
lymphomas (Lym), 49 MM, 43 AL, 23 solid tumors (ST), 2 others;
42 allogeneic (allo-SCT): 11 AL, 11 CML, 8 MDS, 6 AA, 3 Lym,
3 others. Nineteen auto-SCT and 10 allo-SCT were tandem.
Median age was 44 years (3–65), 160 male and 121 female for
auto-SCT, 39 years (6–58), 26 male and 16 female for allo SCT.
The conditioning regimens were: CVB, BEAC, BEAM in Lym;
BuCy in AL; Melfalan in MM; Maxi-ICE in ST; Cy-ATG in AA.
We used a maintenance treatment in ALL with Mtx and 6 MP.
Stem cells mobilized with G-CSF were obtained from BM in 16,
BM  PB in 127, and PB in 183. The median MNC and CD34
infused was 9  108/kg and 9  106/kg in auto-SCT and 7 
108/kg and 8  106/kg in allo-SCT. Hematological recovery me-
dian time was: 10 and 11 days for neutrophils; 14 and 18 for
platelets in auto and allo respectively. One hundred days mortality
was 2.6% in auto-SCT, 5.3% in tandem-SCT, and 31% in allo-
SCT; hospitalization median time was 20, 26, and 46 days, respec-
tively. Ten year overall survival in auto-SCT was: NHL 38%; HL
75%; AML 45%; ALL 73%; MM 36%; germinal tumor 63%, and
15% in breast cancer, in auto-SCT tandem was: MM 57%, NHL
60%, and HL 67%, in allo-SCT was: AA 33%, CML 41%; AL
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